| 生物活性 |
Isorhapontigenin is an orally active dietary polyphenol that acts as a potent antioxidant to attenuate reactive oxygen species (ROS) generation, promotes JUN binding to the AP-1 site of the SESN2 promoter to induce SESN2 transcription, triggers MAPK8-dependent JUN activation, and upregulates PPAR-α, PGC-1α, and CPT-1A expression to promote fatty acid oxidation, while also inducing autophagy, apoptosis, and preadipocyte differentiation, inhibiting tumor growth, cell invasion, NF-κB transcriptional activity, P3K/Akt signaling pathway, STAT1 phosphorylation, and MMP-2 expression, and alleviating oxidative stress, inflammatory cytokine release, and triglyceride accumulation, elevating intracellular ATP levels, and promoting Nrf2 nuclear translocation, thereby improving insulin sensitivity and glucose tolerance in adipose tissue and reducing postprandial blood glucose, insulin, and free fatty acid levels, and it can be used for research related to bladder cancer, liver injury, chronic obstructive pulmonary disease, acute lung injury, and type 2 diabetes. |
| IC50 & Target |
|
|
|
CPT-1A
|
MMP-2
|
PPARα
|
PPARγ
|
FOXO1
|
IL-6
|
|
体外研究 (In Vitro) |
Isorhapontigenin (1.25-40 μM; 24 h) 可在 UMUC3、T24T 和 HeLa 细胞中以剂量依赖的方式诱导自噬,且该自噬作用有助于其抑制 UMUC3 细胞的锚定非依赖性生长。 Isorhapontigenin (2.5-10 μM; 12-24 h) 可通过依赖 JUN 的机制上调 SESN2 的转录水平,该机制是 UMUC3 细胞中自噬诱导及锚定非依赖性生长抑制的必要条件。 Isorhapontigenin (10 μM; 12 h pre-APAP treatment, 24 h post-APAP treatment) 可通过上调 PPAR-α/PGC-1α/CPT-1A 信号通路,减轻对 AML12 细胞中 APAP 诱导的 FAO 失调。 Isorhapontigenin (1-100 μM;预孵育 1 h+刺激 24 h,预孵育 1 h+刺激 10-60 min) 可抑制原代人气道上皮细胞与 A549 细胞释放 IL-6 和 CXCL8,其对 IL-6 的 IC50 值为 17.3-19.7 μM,同时可抑制 NF-κB、AP-1 及 PI3K/Akt/FoxO3A 信号通路。 Isorhapontigenin (1-100 μM; 1 h pre-incubation + 30 min stimulation) 可浓度依赖性地降低经 IL-1β 刺激的 A549 细胞内的 ROS 水平。 Isorhapontigenin (5-15 μM; 12 h pretreatment + 12 h LPS stimulation) 可通过减少促炎介质和活性氧 (ROS) 的生成,对经 LPS 刺激的 RAW264.7 细胞发挥抗炎与抗氧化作用。 Isorhapontigenin (15 μM; 0-24 h direct treatment, 12 h pretreatment + 12 h LPS stimulation) 可在 RAW264.7 细胞中激活 Nrf2 通路,其抗炎/抗氧化作用依赖于 Nrf2 的激活。 Isorhapontigenin (25 μM; 6 days) 可通过提升 PPARγ 的活性与表达,促进 3T3-L1 前脂肪细胞的分化、增强其胰岛素敏感性并降低脂解作用。 Isorhapontigenin (25 μM; 0-12 h) 可通过减少抑制性磷酸化并延缓蛋白酶体降解,提高 3T3-L1 细胞中 PPARγ 的活性与稳定性。 Isorhapontigenin (10-20 μM; 24 h) 可分别特异性抑制 UMUC3 和 T24T 人侵袭性膀胱癌细胞的侵袭能力,且不会影响细胞迁移。 Isorhapontigenin (2.5-20 μM; 6-18 h) 可在人侵袭性膀胱癌 UMUC3 和 T24T 细胞中诱导 FOXO1 蛋白表达呈剂量和时间依赖性上调。 Isorhapontigenin (2.5-20 μM; 3-9 h) 可在转录水平上调人侵袭性膀胱癌细胞 UMUC3 和 T24T 中 foxo1的 mRNA 表达。 Isorhapontigenin (10 μM; 6-18 h) 可在人侵袭性膀胱癌细胞 UMUC3 中以时间依赖性方式增强 FOXO1 启动子活性。 Isorhapontigenin (2.5-10 μM; 12 h) 可在 UMUC3 人侵袭性膀胱癌细胞中以剂量依赖的方式抑制 STAT1 在 Tyr701 位点的磷酸化。 Isorhapontigenin (2.5-20 μM; 18 h) 可呈剂量依赖性地抑制人侵袭性膀胱癌细胞 UMUC3 和 T24T 中 MMP-2 蛋白的表达。
Cell Autophagy Assay
| Cell Line: |
UMUC3, T24T, HeLa |
| Concentration: |
1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM |
| Incubation Time: |
24 h |
| Result: |
Caused a dose-dependent increase in LC3-I to LC3-II conversion in UMUC3, T24T, and HeLa cells. Increased the percentage of GFP-LC3 puncta-positive cells and the number of puncta per cell in a dose-dependent manner in GFP-LC3-transfected UMUC3 cells. |
Western Blot Analysis
| Cell Line: |
UMUC3 |
| Concentration: |
2.5 μM, 5 μM, 10 μM |
| Incubation Time: |
24 h |
| Result: |
Increased SESN2 and BECN1 expression at 2.5-10 μM in UMUC3 cells. Saw its induced LC3-II formation unaffected by BECN1 knockdown in UMUC3 cells. Had its LC3-II formation significantly attenuated in SESN2 knockdown UMUC3 cells. Saw its inhibitory effect on anchorage-independent growth of UMUC3 cells abolished when SESN2 was knocked down. |
Western Blot Analysis
| Cell Line: |
UMUC3 |
| Concentration: |
5 μM, 10 μM |
| Incubation Time: |
6 h, 12 h, 24 h |
| Result: |
Increased MAPK8 phosphorylation in a dose-dependent manner. Had its induced JUN phosphorylation, SESN2 induction, LC3-II formation, SESN2 mRNA expression, and SESN2 promoter activity blocked when MAPK8 was knocked down. Saw its inhibitory effect on anchorage-independent growth of UMUC3 cells abolished when MAPK8 was knocked down. |
Cell Differentiation Assay
| Cell Line: |
3T3-L1 preadipocytes |
| Concentration: |
25 μM |
| Incubation Time: |
6 days (differentiation) |
| Result: |
Promoted lipid accumulation (quantified by Oil Red O staining optical density at 490 nm). Significantly increased mRNA and protein expression of PPARγ target genes (CEBPα, FAS, FABP4, GLUT4) and PPARγ itself. Enhanced insulin-stimulated glucose uptake (1.5-fold over basal). Reduced mRNA and protein levels of hormone-sensitive lipase (HSL). |
Cell Invasion Assay
| Cell Line: |
UMUC3, T24T human invasive bladder cancer cells |
| Concentration: |
10 μM (UMUC3 cells); 20 μM (T24T cells) |
| Incubation Time: |
24 h (UMUC3, T24T cells) |
| Result: |
Reduced relative invasion rate of UMUC3 cells by 63.1% and T24T cells by 61.2% compared to vehicle control; did not affect cell migration under the same conditions. |
Western Blot Analysis
| Cell Line: |
UMUC3, T24T human invasive bladder cancer cells |
| Concentration: |
2.5-10 μM (UMUC3 cells, dose-response); 10-20 μM (T24T cells, dose-response); 10 μM (UMUC3 cells, time-course) |
| Incubation Time: |
12 h (UMUC3, T24T cells, dose-response); 6-18 h (UMUC3 cells, time-course) |
| Result: |
Induced FOXO1 protein expression in a dose-dependent manner in UMUC3 and T24T cells; caused a gradual increase in FOXO1 protein level. |
RT-PCR
| Cell Line: |
UMUC3, T24T human invasive bladder cancer cells |
| Concentration: |
2.5-10 μM (UMUC3 cells, dose-response); 10 μM (UMUC3 cells, time-course); 10-20 μM (T24T cells, dose-response) |
| Incubation Time: |
6 h (UMUC3, T24T cells, dose-response); 3-9 h (UMUC3 cells, time-course) |
| Result: |
Upregulated endogenous foxo1 mRNA expression in a dose-dependent manner in UMUC3 and T24T cells, and in a time-dependent manner in UMUC3 cells; did not affect exogenous flag-foxo1 mRNA expression. |
Western Blot Analysis
| Cell Line: |
UMUC3 human invasive bladder cancer cells |
| Concentration: |
2.5-10 μM |
| Incubation Time: |
12 h |
| Result: |
Dramatically inhibited STAT1 phosphorylation at Tyr701 in a dose-dependent manner without affecting total STAT1 protein expression. |
Western Blot Analysis
| Cell Line: |
UMUC3, T24T human invasive bladder cancer cells |
| Concentration: |
2.5-10 μM (UMUC3 cells); 10-20 μM (T24T cells) |
| Incubation Time: |
18 h (UMUC3, T24T cells) |
| Result: |
Profoundly inhibited MMP-2 protein expression in a dose-dependent manner in both UMUC3 and T24T cells. |
RT-PCR
| Cell Line: |
T24T human invasive bladder cancer cells |
| Concentration: |
10-20 μM |
| Incubation Time: |
18 h |
| Result: |
Attenuated MMP-2 mRNA level in a dose-dependent manner; did not affect MMP-9 mRNA level. |
|
体内研究 (In Vivo) |
Isorhapontigenin (150 mg/kg; daily) 可显著抑制注射 T24T 细胞的裸鼠体内异种移植瘤的生长。 Isorhapontigenin (25-50 mg/kg; i.g;单次给药或者一天一次,连续 3 天) 通过减少细胞凋亡、炎症反应与氧化应激,同时恢复脂肪酸氧化,缓解对乙酰氨基酚诱导的小鼠肝损伤;25 mg/kg 和 50 mg/kg 剂量均显示出有效性。 Isorhapontigenin (51.6 mg/kg; p.o.; daily; 7 days) 可通过减轻炎症反应与氧化应激,有效改善小鼠体内由 LPS 诱导的急性肺损伤。 Isorhapontigenin (25 mg/kg; i.p.; daily; 5 weeks) 可通过调控 PPARγ 改善葡萄糖与胰岛素稳态、增强胰岛素敏感性并调节脂肪组织功能,从而缓解 db/db 小鼠的 2 型糖尿病。 Isorhapontigenin (150 mg/kg/天;饮用水给药;每日给药;持续 20 周) 可抑制 N-Butyl-N-(4-hydroxybutyl)nitrosamine (BBN) (MS-O57586) 诱导的 C57BL/6J 小鼠侵袭性膀胱癌的形成,经其处理的小鼠中仅 16.7%发展为高级别肌层浸润性病变,而仅用 BBN 处理的对照组小鼠的该比例为 100%。
| Animal Model: |
C57BL/6 (male, 6-8 weeks old; Acetaminophen-induced liver injury model) |
| Dosage: |
25 mg/kg; 50 mg/kg |
| Administration: |
i.g. (once, 1 hour after acetaminophen); i.g. (once daily for 3 consecutive days, acetaminophen on day 3); i.g. (once, 1 hour before acetaminophen); i.g. (once, 3 hours after acetaminophen) |
| Result: |
Significantly reduced serum ALT, AST, and LDH levels, centrilobular necrosis area, TUNEL-positive cells, C-PARP expression, serum TNF-α and IL-6 levels, liver MDA levels, and increased liver CAT levels at 25 and 50 mg/kg (post-treatment) compared to acetaminophen alone; reduced lipid accumulation (Oil Red O and BODIPY staining), serum and liver TG levels, increased liver ATP content and FAO activity, and upregulated PPAR-α, PGC-1α, and CPT-1A protein expression at 50 mg/kg (pre-treatment). |
| Animal Model: |
C57BL/6 (male, 6-8 weeks old, 20-25 g, LPS-challenged) |
| Dosage: |
51.6 mg/kg |
| Administration: |
p.o.; daily; 7 days |
| Result: |
Reduced LPS-induced lung injury score, myeloperoxidase (MPO) activity in lung tissues, lung wet/dry weight ratio, and protein concentration in bronchoalveolar lavage fluid (BALF); suppressed LPS-induced increases in BALF concentrations of IL-1β, IL-6, and TNF-α; inhibited p-NF-κB p65 expression and IκB degradation in lung tissues; reduced malondialdehyde (MDA) formation in lung tissues; restored superoxide dismutase (SOD) and glutathione (GSH) activities in lung tissues. |
| Animal Model: |
db/db mice (male, 8 weeks old at treatment start, genetically diabetic model) |
| Dosage: |
25 mg/kg |
| Administration: |
i.p.; daily; 5 weeks |
| Result: |
Reduced postprandial fasting glucose levels by 17.2% after 2 weeks and 40.0% after 5 weeks; reduced insulin levels by 23.2% after 5 weeks; reduced plasma FFA levels by 34.7% after 5 weeks compared to vehicle controls; improved glucose disposal during GTT; enhanced exogenous-insulin-stimulated glucose uptake during ITT; significantly reduced water intake; reduced white adipose tissue adipocyte diameters; significantly increased mRNA expression of PPARγ and its target genes (Fabp4, Glut4, Fas); significantly reduced mRNA and protein levels of HSL; significantly increased insulin-stimulated Akt phosphorylation in white adipose tissue. |
| Animal Model: |
C57BL/6J (male, 5-6 weeks old) injected with N-Butyl-N-(4-hydroxybutyl)nitrosamine |
| Dosage: |
150 mg/kg/day |
| Administration: |
oral via drinking water; daily; 20 weeks |
| Result: |
Reduced the incidence of BBN-induced high-grade muscle-invasive bladder cancer from 100% (12/12 mice) to 16.7% (2/12 mice); caused 7 cases of papillomas and 3 cases of low-grade non-muscle-invasive bladder cancer in treated mice; up-regulated FOXO1 protein expression and down-regulated MMP-2 protein expression in mouse bladder tissues. |
|
| 性状 |
固体 |
| 颜色 |
White to yellow |